grant
MDS-associated U2AF1 mutations induce natural killer cell dysfunction
Organization NATIONAL JEWISH HEALTHLocation DENVER, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2026AML - Acute Myeloid LeukemiaActive Follow-upAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAdoptive Cell TransfersAdvanced DevelopmentAffectAntigen-Presenting CellsB-Cell CLLB-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphogenous LeukemiaB-Cell Chronic Lymphoid LeukemiaB-Cell Lymphocytic LeukemiaB-Lymphocytic LeukemiaBlood CellsCITE sequencingCITE-seqCITEseqCancer TreatmentCancersCell BodyCell DifferentiationCell Differentiation processCell FunctionCell PhysiologyCell ProcessCell ProtectionCellsCellular FunctionCellular Immune FunctionCellular Indexing of Transcriptomes and Epitopes by SequencingCellular PhysiologyCellular ProcessChronic B-Lymphocytic LeukemiaChronic Lymphatic LeukemiaChronic Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaChronic Lymphogenous LeukemiaCo-cultureCocultivationCocultureCoculture TechniquesCytoprotectionCytotoxic cellDNA mutationDataDefectDevelopmentDysfunctionDysmyelopoietic SyndromesEvolutionExperimental ModelsFunctional disorderFunding MechanismsGenesGenetic ChangeGenetic defectGenetic mutationGenomic approachGoalsHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHost DefenseHumanImmuneImmune DiseasesImmune DisordersImmune DysfunctionImmune SurveillanceImmune System DiseasesImmune System DisorderImmune System DysfunctionImmune System and Related DisordersImmune mediated therapyImmune responseImmune systemImmunesImmunologic DiseasesImmunologic SurveillanceImmunological DiseasesImmunological DysfunctionImmunological System DysfunctionImmunologically Directed TherapyImmunosurveillanceImmunotherapyImpairmentIn VitroInduced DNA AlterationInduced MutationInduced Sequence AlterationInflammationInflammatory ResponseK lymphocyteLymphatic cellLymphocyteLymphocyticLytotoxicityMalignant Hematologic NeoplasmMalignant Hematopoietic NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMiceMice MammalsModern ManMolecularMurineMusMutationMyelodysplastic DiseaseMyelodysplastic SyndromesMyelogenousMyeloidMyeloid CellsMyeloid DiseaseMyeloid MalignancyMyeloid NeoplasmMyeloid TumorMyeloproliferative DisordersMyeloproliferative TumorsMyeloproliferative diseaseNK CellsNK cell immune therapyNK cell immunotherapyNK cell therapyNK cell treatmentNK cell-based immune therapyNK cell-based immunotherapyNK cell-based therapyNK cell-based treatmentNK cellular immunotherapyNK cellular therapyNK immunotherapyNK therapyNK treatmentNatural Killer Cell ImmunotherapyNatural Killer CellsOrthologOrthologous GenePathogenesisPatientsPeripheral Blood CellPhysiopathologyProductionPrognosisRNA SeqRNA sequencingRNAseqRefractory Anemia with an Excess of BlastsRefractory anaemia with excess blastsSecondary toSmoldering LeukemiaSpliceosomesSubcellular ProcessSurfaceTechnologyTestingTherapeuticTherapeutic InterventionTumor CellWorkaccessory cellactive followupacute granulocytic leukemiaacute myeloid leukemiaadoptive cell therapyadoptive cellular therapyanti-cancer therapyblood cancercancer immunologycancer of bloodcancer of the bloodcancer therapycancer-directed therapycandidate identificationcellular differentiationcellular indexing of transcriptomes and epitopes by single cell sequencingchronic lymphoid leukemiacytokinecytoprotectivecytotoxiccytotoxicitydevelopmentalfightingfollow upfollow-upfollowed upfollowupfunctional improvementgene productgenome mutationgenomic effortgenomic strategyhost responseimmune functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimprove functionimprovedimproved functional outcomesin vivoinsightintervention therapylymph cellmalignancymyelodysplasiamyeloproliferative neoplasmnatural killer cell based immune therapynatural killer cell based immunotherapynatural killer cell therapynatural killer cell treatmentnatural killer cell-based therapynatural killer cellular therapynatural killer therapyneoplasm immunologyneoplasm/cancerneoplastic cellnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpathophysiologyreceptor expressiontherapeutically effectivetranscriptome sequencingtranscriptomic sequencingtumortumor immunology
Description preview
PROJECT SUMMARY/ABSTRACT
Therapeutic approaches that harness the immune system to target tumors are revolutionizing the cancer
treatment field. Natural Killer (NK) Cells are innate lymphocytes that regulate inflammatory and immune
responses and that directly and indirectly kill tumor cells. While NK cell-harnessing immunotherapies have
shown great…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click